To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Opiates: Misuse
Monday 26th January 2015

Asked by: Lord Patel of Bradford (Non-affiliated - Life peer)

Question to the Department of Health and Social Care:

To ask Her Majesty’s Government what assessment they have made of the reasons for the 32 per cent rise in the number of deaths from heroin or morphine abuse between 2012 and 2013; and how many of the 765 people who died as a result of heroin or morphine abuse in 2013 had left drug treatment in the month that preceded their death.

Answered by Earl Howe - Deputy Leader of the House of Lords

At this stage it is not possible to draw any definitive conclusions about a longer-term trend in deaths from one year’s data. Public Health England is currently analysing the data to better understand the reasons for the increase.


Written Question
Sexual Dysfunction
Monday 18th August 2014

Asked by: Lord Patel of Bradford (Non-affiliated - Life peer)

Question to the Department of Health and Social Care:

To ask Her Majesty’s Government what is the "overall policy objective" referred to at paragraph 21, page 9 of their consultation response <i>Proposed changes to NHS availability of erectile dysfunction treatments—changing prescribing restrictions for generic sildenafil</i>.

Answered by Earl Howe - Deputy Leader of the House of Lords

On 25 June 2014, the Department published the Government’s response to its consultation, Proposed changes to NHS availability of erectile dysfunction treatments: changing prescribing restrictions for sildenafil, a copy of which has been placed in the Library and which is available at:

www.gov.uk/government/uploads/system/uploads/attachment_data/file/322464/ED_Cons_response.pdf

This explains the overall policy objective of amending Regulations governing National Health Service provision of some treatments for erectile dysfunction in a way that has benefits for patients, is affordable for the NHS and is consistent with European Union legislation.